Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review
IntroductionA growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary interve...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1609071/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222422270574592 |
|---|---|
| author | Jacob J. Gries Hafeez Ul Hassan Virk Zhen Wang Zhen Wang Mahboob Alam Samin Sharma Markus Strauss Markus Strauss Chayakrit Krittanawong |
| author_facet | Jacob J. Gries Hafeez Ul Hassan Virk Zhen Wang Zhen Wang Mahboob Alam Samin Sharma Markus Strauss Markus Strauss Chayakrit Krittanawong |
| author_sort | Jacob J. Gries |
| collection | DOAJ |
| description | IntroductionA growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) [2,3]. However, a limited number of studies have evaluated the impact of MASLD on the outcomes of these interventions.MethodsA comprehensive search of the PubMed/MEDLINE and Embase databases was conducted to identify relevant studies from August 2015 to August 2025 using a combination of Medical Subject Headings (MeSH) terms and text words related to MASLD and cardiovascular revascularization.ResultsTwo hundred nineteen papers from the PubMed/MEDLINE and Embase databases were reviewed. Six met the inclusion criteria (
Figure 1). Five studies covered PCI, and one covered CABG. Supplemental information was added using targeted PubMed/MEDLINE searches.ConclusionsMASLD may pose an increased risk of in-hospital and long-term mortality following PCI. Risks for cardiogenic shock, cardiac arrest, in-stent thrombosis, gastrointestinal bleeding, or invasive mechanical ventilation following PCI may also be increased. Further studies are needed to determine the optimal coronary revascularization method and post-revascularization medical therapy for patients with MASLD. |
| format | Article |
| id | doaj-art-c9a0d8bb62de41669bc9aec55c110a6a |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-c9a0d8bb62de41669bc9aec55c110a6a2025-08-26T05:28:10ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-08-011210.3389/fcvm.2025.16090711609071Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic reviewJacob J. Gries0Hafeez Ul Hassan Virk1Zhen Wang2Zhen Wang3Mahboob Alam4Samin Sharma5Markus Strauss6Markus Strauss7Chayakrit Krittanawong8Department of Gastroenterology, Allegheny Health Network, Pittsburgh, PA, United StatesHarrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, United StatesRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United StatesDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United StatesThe Texas Heart Institute, Baylor College of Medicine, Houston, TX, United StatesCardiac Catheterization Laboratory of the Cardiovascular Institute, Mount Sinai Hospital, New York, NY, United StatesDepartment of Cardiology, Sector Preventive Medicine, Health Promotion, Faculty of Health, School of Medicine, University Witten/Herdecke, Hagen, GermanyDepartment of Cardiology I—Coronary and Periphal Vascular Disease, Heart Failure Medicine, University Hospital Muenster, Muenster, GermanyHumanX, Delaware, DE, United StatesIntroductionA growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) [2,3]. However, a limited number of studies have evaluated the impact of MASLD on the outcomes of these interventions.MethodsA comprehensive search of the PubMed/MEDLINE and Embase databases was conducted to identify relevant studies from August 2015 to August 2025 using a combination of Medical Subject Headings (MeSH) terms and text words related to MASLD and cardiovascular revascularization.ResultsTwo hundred nineteen papers from the PubMed/MEDLINE and Embase databases were reviewed. Six met the inclusion criteria ( Figure 1). Five studies covered PCI, and one covered CABG. Supplemental information was added using targeted PubMed/MEDLINE searches.ConclusionsMASLD may pose an increased risk of in-hospital and long-term mortality following PCI. Risks for cardiogenic shock, cardiac arrest, in-stent thrombosis, gastrointestinal bleeding, or invasive mechanical ventilation following PCI may also be increased. Further studies are needed to determine the optimal coronary revascularization method and post-revascularization medical therapy for patients with MASLD.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1609071/fullcoronary heart diseaseMASLDcoronary revascularisationliver diseasecoronary diseasemetabolic dysfunction-associated fatty liver disease (MASLD) |
| spellingShingle | Jacob J. Gries Hafeez Ul Hassan Virk Zhen Wang Zhen Wang Mahboob Alam Samin Sharma Markus Strauss Markus Strauss Chayakrit Krittanawong Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review Frontiers in Cardiovascular Medicine coronary heart disease MASLD coronary revascularisation liver disease coronary disease metabolic dysfunction-associated fatty liver disease (MASLD) |
| title | Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review |
| title_full | Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review |
| title_fullStr | Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review |
| title_full_unstemmed | Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review |
| title_short | Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review |
| title_sort | outcomes of coronary revascularization in patients with metabolic dysfunction associated steatotic liver disease a systematic review |
| topic | coronary heart disease MASLD coronary revascularisation liver disease coronary disease metabolic dysfunction-associated fatty liver disease (MASLD) |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1609071/full |
| work_keys_str_mv | AT jacobjgries outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT hafeezulhassanvirk outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT zhenwang outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT zhenwang outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT mahboobalam outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT saminsharma outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT markusstrauss outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT markusstrauss outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview AT chayakritkrittanawong outcomesofcoronaryrevascularizationinpatientswithmetabolicdysfunctionassociatedsteatoticliverdiseaseasystematicreview |